Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 10, 2026

Reusable Single Cell for Iterative Epigenomic Analyses
10:28

Reusable Single Cell for Iterative Epigenomic Analyses

Published on: February 11, 2022

1.7K

Epigenomics AG.

Christoph Sachsenmaier1, Achim Plum1

  • 1Epigenomics AG, Kleine Präsidentenstr. 1, 10178 Berlin, Germany. christoph.sachsenmaier@epigenomics.com www.epigenomics.com.

Personalized Medicine
|May 24, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic immune cell quantification for diagnostic evaluation and monitoring of patients with inborn errors of immunity and secondary immune deficiencies.

Clinical immunology (Orlando, Fla.)·2024
Same author

Proceedings of the 14th International Newborn Brain Conference: Other forms of brain monitoring, such as NIRS, fMRI, biochemical, etc.

Journal of neonatal-perinatal medicine·2023
Same author

Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutation.

The Journal of allergy and clinical immunology·2022
Same author

Proceedings of the 13th International Newborn Brain Conference: Neuroprotection strategies in the neonate.

Journal of neonatal-perinatal medicine·2022
Same author

Clinical Resistome Screening of 1,110 <i>Escherichia coli</i> Isolates Efficiently Recovers Diagnostically Relevant Antibiotic Resistance Biomarkers and Potential Novel Resistance Mechanisms.

Frontiers in microbiology·2019
Same author

Integrating Culture-based Antibiotic Resistance Profiles with Whole-genome Sequencing Data for 11,087 Clinical Isolates.

Genomics, proteomics & bioinformatics·2019
Same journal

The impact of the rise of the chatbots: transforming genetics clinical delivery and research.

Personalized medicine·2026
Same journal

Digital biomarkers in chronic disease management: a systematic review of personalization and ethical challenges.

Personalized medicine·2026
Same journal

Toward a harmonized assessment of MRD by NGS: blinded pilot study of NGS assays by MPAACT consortium.

Personalized medicine·2026
Same journal

Expression levels of microRNA-550a-5p in patients with spinal metastases from non-small cell lung cancer.

Personalized medicine·2026
Same journal

Epigenetic and genetic insights for tailored therapeutic strategies in multiple sclerosis.

Personalized medicine·2026
Same journal

Deciphering the multi-organ anti-fibrotic mechanisms of pirfenidone and nintedanib via network pharmacology.

Personalized medicine·2026
See all related articles

DNA methylation biomarkers enable earlier disease detection and personalized treatments. Epigenomics AG develops innovative in vitro diagnostic tests for cancer screening, prognosis, and predicting drug response.

Area of Science:

  • Biomarkers and Diagnostics
  • Epigenetics
  • Oncology

Background:

  • Early disease diagnosis and personalized treatment are crucial for improving outcomes in life-threatening conditions.
  • DNA methylation is a valuable source of biomarkers for diagnosis, prognosis, and predicting drug response in various diseases, including cancer.

Purpose of the Study:

  • To leverage DNA methylation biomarkers for the development of in vitro diagnostic tests.
  • To create screening tests for early cancer detection in body fluids.
  • To develop molecular pathology tests for cancer prognosis using tissue samples.

Main Methods:

  • Utilizing DNA methylation biomarker technology.
  • Developing in vitro diagnostic assays.
  • Collaborating with pharmaceutical and biotechnology companies for drug development support.
Keywords:
DNA methylationbiomarkerbody fluidscancerdiagnosisdrug response predictionin vitro diagnosticsmolecular pathologypatient stratificationprognosisscreeningtissue testing

More Related Videos

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery
07:49

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery

Published on: May 30, 2025

2.5K
Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome
12:25

Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome

Published on: February 24, 2023

1.3K

Related Experiment Videos

Last Updated: Feb 10, 2026

Reusable Single Cell for Iterative Epigenomic Analyses
10:28

Reusable Single Cell for Iterative Epigenomic Analyses

Published on: February 11, 2022

1.7K
CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery
07:49

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery

Published on: May 30, 2025

2.5K
Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome
12:25

Cell-Specific Paired Interrogation of the Mouse Ovarian Epigenome and Transcriptome

Published on: February 24, 2023

1.3K

Main Results:

  • A product pipeline including early cancer detection screening tests and molecular pathology tests for prognosis.
  • Application of technology for patient stratification and drug response prediction in drug development.

Conclusions:

  • DNA methylation biomarkers offer significant potential for improving disease diagnosis, prognosis, and treatment selection.
  • Epigenomics AG's technology platform supports the development of novel diagnostic tools and aids in pharmaceutical research and development.